In vivo production and delivery of insulinotropin for gene therapy

   
   

The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP 1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy, in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. The present invention includes primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, other somatic cells that can be cultured, and somatic cell precursors, which have been transfected with exogenous DNA encoding EPO or an insulinotropin that is stably integrated into their genomes or is expressed in the cells episomally.

A invenção atual relaciona-se a transfected preliminar e as pilhas somatic secundárias da origem vertebrate, particularmente origem mammalian, transfected com material genetic exogenous (DNA) que codifica o erythropoietin ou um insulinotropin (por exemplo, os derivatives glucagon-como do peptide 1 (GLP 1)), os métodos por que as pilhas preliminares e secundárias são transfected para incluir o erythropoietin codificando material genetic exogenous ou um insulinotropin, métodos de produzir tensões clonal da pilha ou as tensões heterogenous da pilha que erythropoietin expresso ou um insulinotropin, os métodos da terapia do gene, em que transfected preliminar ou as pilhas secundárias são usadas, e os métodos de produzir usar-se dos antibodies transfected pilhas preliminares ou secundárias. A invenção atual inclui pilhas somatic preliminares e secundárias, tais como fibroblasts, keratinocytes, pilhas epithelial, pilhas endothelial, pilhas glial, pilhas neural, elementos dados forma do sangue, pilhas do músculo, outras pilhas somatic que podem ser cultivadas, e os precursors da pilha somatic, que foram transfected com o DNA exogenous que codifica o EPO ou um insulinotropin que fosse integrado estàvel em seus genomes ou expressado nas pilhas episomally.

 
Web www.patentalert.com

< Induction of beta cell differentiation in human cells by stimulation of the GLP-1 receptor

< Glucagon-like insulinotropic peptides, compositions and methods

> Prolonged delivery of peptides

> Human glucose-dependent insulin-secreting cell line

~ 00122